Lucid Diagnostics receives Medicare payments and closes $15 million financing
Lucid Diagnostics ($LUCD) said it has begun receiving Medicare reimbursement for its EsoGuard esophageal cancer test at the established rate of $1,938.01 per test. The announcement advances the reimbursement story from submission of claims to actual payments, an important commercial milestone for converting testing activity into cash receipts. The company also disclosed completion of a $15 million private placement of Series C convertible preferred stock with existing investors. Preferred shares
0